Skip to main content
. 2011 Jul 14;11:295. doi: 10.1186/1471-2407-11-295

Table 1.

Patients' characteristics

n (%)
Sex male 26 (74.3)
female 9 (25.7)
total 35 (100)
MSKCC risk favourable 2 (5.7)
intermediate 21 (60.0)
poor 4 (11.4)
unknown 8 (22.9)
ECOG status 0 21 (60)
1 9 (25.7)
> 1 1 (2.9)
unknown 4 (11.4)
Histology clear cell 29 (82.7)
papillary 4 (11.4)
other 2 (5.9)
Previous immunotherapy 14 (40)

Abbreviations:

MSKCC - Memorial Sloan-Kettering Cancer Center;

ECOG - Eastern Cooperative Oncology Group;

rTKI - receptor tyrosine kinase inhibitor.